Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023
01 août 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2023...
Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance
31 juil. 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
-- FY 2023 Adjusted non-GAAP earnings per share now expected to be $4.40 - $4.701 ---- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP R&D...
Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)
24 juil. 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century1 – CAL02 is a unique therapeutic agent that works differently...
Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance
15 juin 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and reiterated its 2023 financial...
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension
14 juin 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
– Company believes CAL02 is a new chemical entity (NCE), which would result in five years of marketing exclusivity upon approval or three years without NCE designation; total potential of eight or ten...
Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at the Society for Academic Emergency Medicine (SAEM) Annual Meeting
11 mai 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that two abstracts were accepted for presentation at the...
Eagle Pharmaceuticals Reports First Quarter 2023 Results
09 mai 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income1 was $1.27 per basic and...
Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®¹ (remimazolam for injection) from CMS
01 mai 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
-- Byfavo1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) --...
Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023
27 avr. 2023 16h30 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023...
Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride)
05 avr. 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Dr....